MyFinsight
Home
Blog
About
Proceeds from exercise of
common stock options
$156K
Net cash provided by
(used in) financing...
$156K
Net increase in
cash, cash...
-$289,139K
Canceled cashflow
$156K
Proceeds from maturities
of marketable...
$33,000K
Accrued expenses and
other current...
$4,632K
Stock-based compensation
$3,222K
Depreciation and
amortization
$879K
Accounts payable
$866K
Operating lease
right-of-use assets
$599K
Net cash (used in)
provided by investing...
-$268,708K
Net cash used in
operating activities
-$20,587K
Canceled cashflow
$33,000K
Canceled cashflow
$10,198K
Purchases of marketable
securities
$300,446K
Net loss
-$24,144K
Purchases of property and
equipment
$1,262K
Deferred revenue
-$3,384K
Prepaid expenses and
other current assets
$1,619K
Net amortization of
premiums and accretion of...
-$1,033K
Operating lease
liabilities
-$350K
Interest receivable
$144K
Other assets
$111K
Back
Back
Cash Flow
Aktis Oncology, Inc. (AKTS)
Aktis Oncology, Inc. (AKTS)
source: myfinsight.com